<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To assess the effect of orlistat on body weight and concomitant diseases in patients with body mass index (BMI) of &gt; 28 kg/m2 and poorly controlled type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> or <z:e sem="disease" ids="C0020443" disease_type="Disease or Syndrome" abbrv="">hypercholesterolaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This trial was a six-month, randomized, double-blind, placebo-controlled study of orlistat 120 mg three times daily plus a mildly reduced-calorie diet </plain></SENT>
<SENT sid="2" pm="."><plain>1004 <z:mp ids='MP_0001261'>obese</z:mp> patients (BMI 28-40 kg/m2) were included by 253 private endocrinologists and received orlistat (n = 499) or placebo (n = 505) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were stratified by concomitant disorder (type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, n = 193; <z:hpo ids='HP_0000822'>hypertension</z:hpo>, n = 614; <z:e sem="disease" ids="C0020443" disease_type="Disease or Syndrome" abbrv="">hypercholesterolaemia</z:e>, n = 197) </plain></SENT>
<SENT sid="4" pm="."><plain>Body weight, anthropometry, <z:chebi fb="23" ids="18059">lipid</z:chebi> and glycaemic control parameters and blood pressure </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: After six months, orlistat produced a significantly greater <z:hpo ids='HP_0001824'>weight loss</z:hpo> than placebo in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (-4.2% vs. -1.4%), <z:hpo ids='HP_0000822'>hypertension</z:hpo> (-6.2% vs. -1.9%) and <z:e sem="disease" ids="C0020443" disease_type="Disease or Syndrome" abbrv="">hypercholesterolaemia</z:e> (-5.5% vs. -2.3%) groups (p &lt; 0.0001 for <z:hpo ids='HP_0000001'>all</z:hpo>) </plain></SENT>
<SENT sid="6" pm="."><plain>There was a greater decrease in HbA(1c) in the type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> group (-0.54 vs. -0.18%; p = 0.002) and <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>)-cholesterol in the <z:e sem="disease" ids="C0020443" disease_type="Disease or Syndrome" abbrv="">hypercholesterolaemia</z:e> group (-11.7% vs. -4.5%; p = 0.004) with orlistat vs. placebo </plain></SENT>
<SENT sid="7" pm="."><plain>Early <z:hpo ids='HP_0001824'>weight loss</z:hpo> (&gt; or = 5% at 12 weeks) was associated with the highest <z:hpo ids='HP_0001824'>weight loss</z:hpo> in each group, and the highest decreases in HbA1c, <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> and diastolic blood pressure in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:e sem="disease" ids="C0020443" disease_type="Disease or Syndrome" abbrv="">hypercholesterolaemia</z:e> and <z:hpo ids='HP_0000822'>hypertension</z:hpo>, respectively, at six months </plain></SENT>
<SENT sid="8" pm="."><plain>The incidence of adverse events was similar for orlistat and placebo, except for certain generally well-tolerated gastrointestinal events that were more common with orlistat </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Orlistat plus a mildly reduced-calorie diet produced clinically meaningful <z:hpo ids='HP_0001824'>weight loss</z:hpo> and improvements in risk factors in overweight and <z:mp ids='MP_0001261'>obese</z:mp> patients with poorly controlled type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> or <z:e sem="disease" ids="C0020443" disease_type="Disease or Syndrome" abbrv="">hypercholesterolaemia</z:e> </plain></SENT>
</text></document>